Cytokines, notably the interleukins IL-6 and IL-IO, have an important role in the development and progression of renal-cell carcinomas, acting in the host-tumor interaction and in tumor bulk. Heat shock proteins (HSP), in particular HSP-90, may have a regulatory role in cytokine biosynthesis and prognostic implication in some tumors. To define the roles of the cytokines IL-6 and IL-IO and HSP-90 in the progression of renal-cell carcinoma we analyzed immunohistochemical expression of these proteins in human renal-cell carcinomas from 95 total nephrectomies. IL-6, IL-IO and HSP-90 proteins were more strongly expressed in epithelium and stroma of the renal tumoral compartment than in adjacent normal peritumoral tissue. But the difference reached significance only for HSP-90 protein. The percentage of cells expressing IL-6, IL-IO and HSP-90 immunoreactivity was higher in benign epithelial tumors, than in normal peritumoral tissue, but lower than in renal-cell carcinomas. Whereas HSP-90 immunoreactivity seemed higher in more aggressive histological phenotypes (collecting-duct carcinoma) of renal-cell carcinomas, IL-IO protein levels were higher in more advanced TNM stage (pT3) tumors. Our observation suggests that IL-6 and IL-IO and HSP-90 may be useful markers associated with the development and progression of renal-cell carcinomas and have independent functional roles in this malignant condition.
21 and 28 kDa, is involved in regulating a multitude of cellular functions, including cancer proliferation and differentiation, apoptosis and angiogenesis, and in modulating immune responses through immune cell differentiation (9) . The anti-inflammatory cytokine IL-IO is a pleiotropic cytokine that has conflicting roles in the development of cancer. IL-l 0 may exert an antitumor effect by down-regulating the synthesis of vascular endothelial growth factor or by controlling tumor metastasis by down-regulating class I expression, in tum enhancing tumor cell lysis (4) . IL-IO acts also as a tumor promoter, influencing tumor escape from the immune response by suppressing type I helper T (Th I) cytokine production (4, 10) . The presence of IL-l 0 in many tumors may influence native antitumor responses because IL-IO is secreted by regulatory T cells and inhibits dendritic cell function, thus inducing a response against tumor cells (11) (12) .
Cancer cells are always under moderate-to-severe stress to which they respond by increasing synthesis of various molecular chaperones. The widelyexpressed molecular chaperone heat shock protein-90 (HSP-90) has emerged as the most important for tumor cell growth or survival, or both, and influences the activity and stability of a wide range of 'client' proteins that regulate cellular growth, differentiation and death pathways (13) (14) (15) (16) . Client proteins of HSP-90 include many overexpressed or mutated oncogenes, critical for the phenotype transformation observed in tumors (16) . Although HSP is largely latent in unstressed normal cells (17) , HSP-90 expression may be up-regulated in various tumors (6) (7) (18) (19) (20) (21) and play an important role in heterodimeric hypoxia-inducible factor-l (HIF-l) stabilization (22) . HIF-l is involved in key steps of tumor progression and therapy resistance and thus represents an attractive antitumor target (22) (23) . Inhibition of HSP-90 causes, through pleiotropic mechanisms, the destabilization and degradation of a large number of 'client proteins' (16) . HSP-90 inhibitors offer the potential to treat a variety of human tumors (16) . In the kidney, the best characterized function of HSP-90 is its interaction with the mineralocorticoid receptors, because of its binding to aldosterone. Little is known about the expression of HSP-90 isoforms and their regulation in the kidney (23) (24) . Because of the potential importance of HSP-90 isoforms as mediators of aldosterone function, this protein may be involved in various processes along the nephron, being expressed more abundantly in the medulla than in the renal cortex (24) .
Because HSP-90 inhibitors have shown promising activity in both in vitro and in vivo preclinical model systems and have particular importance in the hosttumor immune response (21) , HSP-90 seems to offer a unique anticancer strategy of considerable promise (16) (17) (18) 25) .
Toour knowledge, no immunohistochemical studies have yet sought IL-6, IL-l 0 and HSP-90 in human renal tissue from patients undergoing total nephrectomy for renal neoplasms. Most studies examined IL-6 and IL-10 expression mainly in human renal cell lines, culture supernatant and peripheral blood, with various methods [immunoassay, Western Blot, immunohistochemistry, and reverse-transcript polymerase chain reaction (RT-PCR) analysis] (26) (27) (28) .
Extending our previous research investigating the role of cytokines and HSPs in the diagnosis and prognosis ofurogenital neoplasia (6) (7) , in this in vivo study we analyzed the role of the IL-6 and IL-l 0 and HSP-90 in the progression ofhuman RCC. Todo so we characterized, by immunohistochemistry, epithelial and stromal expression of these proteins in normal peritumoral renal tissue and renal cell carcinoma (RCC) areas from 95 patients undergoing radical nephrectomy, and quantified immunohistochemical levels by computer-assisted image analysis. We then determined the possible association of IL-6, IL-IO and HSP-90 immunoreactivity with histopathologic features, tumor grade and stage.
MATERIALS AND METHODS

Tumor Samples
Ninety-five formalin-fixed, paraffin-embedded renal specimens were obtained from 95 patients (age range 51 to 88 years, mean age 68.11 years) who had undergone total nephrectomy for primary RCC in the Department of Urology "U. Bracci" University "La Sapienza", Rome (Italy) from 1997 to 2003. Tumors were classified, graded and staged according to the RCC classification of the American Joint Committee on Cancer 2002 (29) and the WHO 2004 (3). Of the 95 tumors studied, 10 (10.52%) showed the morphological features of benign epithelial tumors (4 papillary adenomas and 6 oncocytomas). The remaining 85 tumors (89.48%) were RCCs: 56 (65.88%) were clear-cell, 13 (15.29%) papillary renal cell, 9 (10.58%) chromophobe cell, 2 (2.35%) spindle-cell and 5 (5.88%) collecting-duct carcinoma subtypes. According to histological grading (30), 23/85 (27.05%) were graded G I, 37/85 (43.52%) G II and 25/85 (29.41%) GIll/IV. According to tumor-node-metastasis (TNM) pathological staging 32/85 (37.64%) tumors were pTl, 14/85 (16.47%) pT2, and 39/85 (45.88%) pT3/T4.
Tissue MaxArray (TMA) Construction
High-density TMAs were assembled using the manual tissue puncher/array (Beecher Instruments, Silver Springs, MD) as already described (7) . Multiple replicate core samples of normal tissue adjacent to tumoral area and RCC tissue were acquired from each case.
Immunohistochemical staining
Samples were immunostained with the anti-IL6 mouse purified recombinant human IL-6 (supplied by Genzyme, Diagnostics, Cambridge, MA, USA); anti-Ill 0 rabbit recombinant human IL-IO (supplied by Genzyme, Diagnostics, Cambridge, MA, USA) and anti-HSP90 (clone 0-19) rabbit polyclonal antibody IgG I/K fraction (supplied by Novocastra, Laboratories Ltd, Newcastle, UK), at I: 100 dilution and incubated overnight at 4°C as previously reported (6) (7) .
Immunohistochemical evaluation by computerassisted image analysis (IHC)
To quantify IL-6, ILiO and HSP-90 immunoreactivity in tissue sections, and reduce operator subjectivity, we used computer-assisted image analysis. Three representative areas of each sample (assessed by IHC) were randomly selected for each tumor tissue sample from the normal tissue adjacent to tumoral areas and RCC under a light microscope Olympus Uplan FI (20x objective), and captured with a digital camera (Nikon). Areas of interest were quantified with IMAGE-Pro Plus 4.5 software (Media Cybernetics, Silver Spring, MD, USA) using the histogram function of the software, as already described (7, 31) .
Statistical analysis
The results are reported as mean ± standard error (SE) and expressed in arbitrary densitometric units. The data were analyzed by the Multistat program (Biosoft, Cambridge, 1988). Paired Student 50 t-test and chi-square test were used to analyze differential expression of IL-6, ILI0 and HSP-90 proteins in the epithelial and stromal compartments of the normal tissue adjacent to tumoral areas and RCC examined. A possible correlation between the various proteins in the three neoplastic and nonneoplastic areas was determined by linear regression analysis using rank correlation. Chi-square test was used to determine the association of IL-6, ILI0 and HSP-90 Table I . Evaluation of interleukin-6 (IL-6), IL-IO and heat-shock protein-90 (HSP-90) protein expression in epithelium and stroma of95 renal epithelial neoplasias by computer-assisted quantitative image analysis. HSP-90 epithelial expression was significantly higher than stromal expression only in the tumoral areas ( 
RESULTS
In the 95 renal neoplasias examined, IL-6, IL-IO and HSP-90 proteins were more strongly expressed in the epithelium and stroma of the renal tumoral compartment than in adjacent normal peritumoral tissue ( Fig. 1) . IL-6, IL-IO and HSP-90 expression levels were higher in epithelium than in the stroma of both tumoral and peritumoral normal tissue, the difference reached significance only for HSP-90 protein in the renal neoplastic areas (22.04±0.15 vs 11.37±0.99; P = 0.043 by chi-square test) (Table  I) . IL-6, IL-IO and HSP-90 showed cytoplasmic immunoreactivity. Immunostaining patterns of expression differed in normal peritumoral tissue and kidney tumor (Table I) .
In normal renal peritumoral epithelium, IL-6, IL-IO and HSP-90 expression was focal. IL-6 immunoreactivity was distributed only in renal tubules, whereas IL-l 0 was present in renal tubules and also in renal corpuscles. Conversely, HSP-90 immunoreactivity was mainly localized in the cytoplasm ofthe epithelium lining the proximal and distal convoluted tubules and collecting ducts. Renal corpuscles showed a patchy distribution of IL-IO and HSP-90, localized in the mesangial cells and podocytes (Fig. 2 A) . Normal renal peritumoral stroma expressed scarce and very weak IL-6, IL-IO and HSP-90 immunoreactivity, localized when present, mainly in mononuclear and endothelial cells.
In tumoral tissue, the immunohistochemical analysis of epithelial renal tumor showed diffuse, moderate to strong cytoplasmic staining for IL-6, IL-IO and HSP-90 according to the histological type of renal tumors (Table II) . The percentage of cells expressing IL-6, IL-IO and HSP-90 immunoreactivity was higher in benign epithelial tumors (papillary adenoma and oncocytoma) than in normal peritumoral tissue (Fig. 2B ), but lower than in RCCs (Table II) . IL-6, IL-IO and HSP-90 expression differed appreciably, though not significantly according to the different histological subtype of RCC: the mean of percentage of tumoral areas stained for IL-6 and IL-IO was slightly increased within RCC clear-cell, papillary renal cell and chromophobe cell subtypes, whereas the percentage of tumor areas stained for HSP-90 was slightly increased within spindle-cell and collectingduct carcinoma subtype tumors (Table II, Fig. 3 ). In the TableII. /nterleukin-6 (/L-6), /L-10 and heat-shock protein (HSP-90) expression in histological subtypes ofrenal tumors. and stroma of all RCCs examined, HSP-90 levels were higher than IL-6 and IL-IO ( Fig. 4) . Although all the proteins investigated reached higher levels in epithelial and interstitial renal tissue from higher-grade (grade llUIV) and higher-stage (PT3) than from lower-grade (I or II) and lower-stage (pTl and pT2) RCCs, no correlation was found between IL-6, IL-IO and HSP-90 immunoreactivity and tumor grade and stage (Table III) 
DISCUSSION
Collectively these in vivo immunohistochemical findings show that most RCCs express the cytokines IL-6 and IL-IO and HSP-90. Higher levels of IL-6 in RCC tumors than in normal kidney agree with previous studies in cell lines and fresh tumor (32) (33) , suggesting that IL-6 is produced by normal renal epithelial cells and kept by these cells at low basal levels. This finding is in line with the observation that most RCCs arise from proximal tubules (34) , which have the ability to produce several immunomodulatory cytokines such as IL-6, IL-8, transforming growth factor-Bl , and TNF-alpha (5, (32) (33) (34) . Because the IL-6 regulatory mechanism is disrupted in renal cancer, IL-6 acts as an autocrine growth factor for RCC (26) . The significant upregulation of IL-6 and IL-l 0 we found in malignant but not in normal renal tissue, and the positive correlation between IL-6 and IL-IO proteins, reinforces the known differential role of the various cytokines in normal and tumor cells. The differential IL-6 and IL-I0 expression we found in benign tumors and RCCs --higher IL-6 epithelial and stromal immunoreactivity than IL-I0 in benign tumors (papillary adenoma and oncocytoma) and lower than IL-IO in RCCs --, fits in well with previous observations showing that RCCs produce large amounts of proinflammatory and T-cellinhibitory cytokines that may exert tumor-promoting and immunosuppressive effects (35) (36) . IL-I0 has been traditionally regarded as an anti-inflammatory, , IL-I 0 and heat-shock protein-90 (HSP-90) immunoreactivity in 95 nephrectomies : comp arison between ep ithelium and stroma ofnormal and tumoral tissues. In the epithelium and stroma, IL-6 and IL-IO and HSP-90 expression was higher in tumoral than in normal renal tissue. In the tumors. HSP-90 ep ithelial levels were significantly higher than stromal levels (P<.05, by chi-square test).
immunosuppressivecytokinethatfavorstumorescape from immune surveillance and as a potent inhibitor of the synthesis of other cytokines, particularly IL-6 . Emerging evidence neverthele ss sugge sts that IL-I 0 also possesses immunostimulating properties, owing to its pleiotropic ability of influencing positively and negatively the function of innate and adapti ve immunity in experimental models ( I I). Hence Il-10, under physiologic conditions is secreted by tubule cells at low levels, but in neoplastic lesions is deregulated and acts as an oncogene (36) .
In line with previous immunohistochemical studies in paraffin-embedded tissue, we confirmed the localization of IL-6 and IL-IO in tumor cells suggesting that RCC produce 11-6 and IL-IO (37) (38) (41) (42) . Recent studies in the peripheral blood showed higher IL-6 and IL-IO levels in patients with RCC than in healthy control s (38) , and a positive correlation between IL-6 and IL-l 0 plasma levels, tumor size, tumor progression and prognosis (4, 26, (38) (39) (40) (41) (42) . In their study investigating IL-IO expression in human RCC, Uwatoko et al (37) reported a decreased incidence of metastasis in patients with IL-IO levels than in those without IL-IO, and no correlation between IL-I 0 expression and prognosis. In our study, neither IL-6 nor IL-l 0 correlated with histologic subtype or pathological grade and stage of RCCs. Collectively these immunohistochemical findings suggest that increased IL-6 and IL-l 0 immunoreactivity in more advanced RCCs may be an independent marker of disease progression in these patients . The positive correlation between HSP-90 , IL-6 and IL-I 0 found in this immunohistoch emical study suggests that the proteins we studied are dependently regulated. IL-6 positively regulates HSP-90 expression via signal transducer and activator transcription 3 (STAT 3) (43) . HSP-90 is therefore an important regulator of IL-6 functions and thereby may have critical roles in the progre ssion of various diseases including cancer (44) (45) .
Consistent with previous observations in rats (44) (45) , in our study of95 specimens from patients who had undergone nephrectomy for RCC, we detected HSP-90 in podocytes and epithelial cells of distal tubules and collecting ducts adjacent to neoplastic tissue, and its levels were higher than those of IL-6 and IL-I O. HSP-90 was nevertheless expressed more strongly in the epithelial compartment of RCC than in normal tissue adjacent to tumoral area (P<.05). HSP-90 expression differed from IL-6 and IL-IO expression in the various histological RCC subtypes. Whereas HSP-90 expression was stronger in more aggressi ve RCCs (collecting-duct carcinoma), IL-6 and IL-IO immunoreactivity was stronger in less aggressive RCCs (papillary renal or chromophobe subtypes), HSP-90 immunoreactivity significantly increasing as the malignancy progressed.
In line with our previous immunohistochemical studies (7) (8) , the stronger immunoreactivity for HSP-90 than for IL-6 and IL-lO which we detected in high-grade and advanced stage tumors suggests that therapy with anti-HSP-90 could improve the prognosis in patients with advanced RCC. The higher levels of IL-I 0 we found in more advanced TNM stage RCC, and the higher HSP-90 levels in more aggressive histological subtypes of RCCs, might be interpreted as evidence that the three proteins investigated act in an autonomous way to promote autocrine growth of invasive malignancy. They also suggest that these proteins may be useful as markers of tumor progression in RCC. In particular, HSP-90 inhibitors, by directly promoting cell death, may be useful in the management of advanced cancers that have developed target-related resistance to specific kinase inhibitors. Their anti-angiogenic activity would be especially advantageous in the treatment of highly vascularized solid tumors (14, 16) .
